Radiation boost may help immunotherapy fight lung cancer

NCT ID NCT03176173

Completed Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding high-dose, precisely targeted radiation to standard immunotherapy can improve outcomes for people with stage IV non-small cell lung cancer. Forty-five adults who were already on immunotherapy received radiation to some of their tumors. Researchers measured how long the cancer stayed under control and whether tumors shrank.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: image-guided radiation therapy (IGRT) plus immunotherapy (anti-PD-1 or anti-PD-L1)
What this could lead to: If it works, this combination could help control metastatic lung cancer better than immunotherapy alone.
What could go wrong: This is a small, completed phase II trial with only 45 participants. Results may not apply to all patients, and radiation can cause side effects like fatigue or lung inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IV NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STAGE IV NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Stanford University, School of Medicine

Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.